Target 2035 - an update on private sector contributions.

Autor: Ackloo S; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca., Antolin AA; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL) L'Hospitalet del Llobregat Barcelona Catalonia Spain aantolin@idibell.cat., Bartolome JM; A Division of Janssen-Cilag S.A., Janssen Research and Development Toledo Spain jbartolo@its.jnj.com JLlaveri@ITS.JNJ.com., Beck H; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com., Bullock A; Center for Medicines Discovery, Old Road Campus, University of Oxford Roosevelt Drive, Headington Oxford OX3 7DQ UK alex.bullock@cmd.ox.ac.uk jon.elkins@cmd.ox.ac.uk., Betz UAK; Merck KGaA Darmstadt Germany ulrich.betz@merckgroup.com Sven.Lindemann@merckgroup.com., Böttcher J; Boehringer Ingelheim RCV GmbH & Co KG Vienna Austria jark.boettcher@boehringer-ingelheim.com., Brown PJ; Structural Genomics Consortium, University of North Carolina at Chapel Hill USA peter.brown@unc.edu., Chaturvedi M; Boehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com., Crisp A; Division of Cancer Therapeutics, The Institute of Cancer Research London SM2 5NG UK Alisa.crisp@icr.ac.uk., Daniels D; Foghorn Therapeutics 500 Technology Square, Suite 700 Cambridge MA 02139 USA DDaniels@foghorntx.com., Dreher J; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com., Edfeldt K; Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden kristina.edfeldt@ki.se michael.sundstrom@ki.se., Edwards AM; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca., Egner U; Nuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany egner.target2035@web.de anke.mueller-fahrnow@nuvisan.com., Elkins J; Center for Medicines Discovery, Old Road Campus, University of Oxford Roosevelt Drive, Headington Oxford OX3 7DQ UK alex.bullock@cmd.ox.ac.uk jon.elkins@cmd.ox.ac.uk., Fischer C; Discovery Chemistry, Merck & Co., Inc. Boston Massachusetts 02115 USA christian_fischer@merck.com., Glendorf T; Research & Early Development, Novo Nordisk A/S Måløv Denmark tgle@novonordisk.com lrli@novonordisk.com., Goldberg S; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Hartung IV; Medicinal Chemistry, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany ingo.hartung@merckgroup.com., Hillisch A; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com., Homan E; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet Stockholm Sweden evert.homan@ki.se maurice.grube@scilifelab.se., Knapp S; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Köster M; Boehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com., Krämer O; Boehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com., Llaveria J; A Division of Janssen-Cilag S.A., Janssen Research and Development Toledo Spain jbartolo@its.jnj.com JLlaveri@ITS.JNJ.com., Lessel U; Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 D-88397 Biberach an der Riss Germany uta.lessel@boehringer-ingelheim.com., Lindemann S; Merck KGaA Darmstadt Germany ulrich.betz@merckgroup.com Sven.Lindemann@merckgroup.com., Linderoth L; Research & Early Development, Novo Nordisk A/S Måløv Denmark tgle@novonordisk.com lrli@novonordisk.com., Matsui H; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited Fujisawa Kanagawa Japan hisanori.matsui@takeda.com., Michel M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet Stockholm Sweden evert.homan@ki.se maurice.grube@scilifelab.se., Montel F; Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 D-88397 Biberach an der Riss Germany florian.montel@boehringer-ingelheim.com., Mueller-Fahrnow A; Nuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany egner.target2035@web.de anke.mueller-fahrnow@nuvisan.com., Müller S; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Owen DR; Discovery Network Group, Pfizer Medicine Design Cambridge MA 02139 USA Dafydd.Owen@pfizer.com., Saikatendu KS; Global Research Externalization, Takeda California, Inc. 9625 Towne Center Drive San Diego CA 92121 USA kumar.saikatendu@takeda.com., Santhakumar V; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca., Sanderson W; Janssen Research & Development, Janssen Pharmaceutica N. V Beerse Belgium WSANDERS@its.jnj.com., Scholten C; Research and Development, Bayer AG, Pharmaceuticals 13353 Berlin Germany cora.scholten@bayer.com., Schapira M; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.; Department of Pharmacology & Toxicology, University of Toronto Toronto Ontario M5S 1A8 Canada., Sharma S; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Shireman B; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Sundström M; Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden kristina.edfeldt@ki.se michael.sundstrom@ki.se., Todd MH; School of Pharmacy, University College London London WC1N 1AX UK mattoddchem@gmail.com., Tredup C; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Venable J; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Willson TM; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA tim.willson@unc.edu., Arrowsmith CH; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.; Princess Margaret Cancer Centre Toronto Ontario M5G 1L7 Canada.

Publikováno v: RSC medicinal chemistry [RSC Med Chem] 2023 Mar 16; Vol. 14 (6), pp. 1002-1011. Date of Electronic Publication: 2023 Mar 16 (Print Publication: 2023).

Target 2035 - update on the quest for a probe for every protein.

Autor: Müller S; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Ackloo S; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca., Al Chawaf A; University of Toronto Toronto Ontario M5G 1L7 Canada., Al-Lazikani B; Department of Data Science, The Institute of Cancer Research London SM2 5NG UK.; CRUK ICR/Imperial Convergence Science Centre London SM2 5NG UK., Antolin A; Department of Data Science, The Institute of Cancer Research London SM2 5NG UK.; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research London SM2 5NG UK., Baell JB; Monash Institute of Pharmaceutical Sciences, Monash University Parkville Victoria 3052 Australia.; School of Pharmaceutical Sciences, Nanjing Tech University No. 30 South Puzhu Road Nanjing 211816 People's Republic of China., Beck H; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany., Beedie S; Centre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK., Betz UAK; Merck KGaA Darmstadt Germany., Bezerra GA; Centre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK., Brennan PE; Alzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, University of Oxford Oxford OX3 7FZ UK., Brown D; Institut Recherches de Servier 125 Chemin de Ronde 78290 Croissy France., Brown PJ; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca., Bullock AN; Centre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK., Carter AJ; Discovery Research, Boehringer Ingelheim 55216 Ingelheim am Rhein Germany., Chaikuad A; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Chaineau M; Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, McGill University Montreal QC Canada., Ciulli A; School of Life Sciences, Division of Biological Chemistry and Drug Discovery, University of Dundee James Black Centre Dundee UK., Collins I; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research London SM2 5NG UK., Dreher J; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany., Drewry D; Structural Genomics Consortium, UNC Eshelman School of Pharmacy Chapel Hill NC USA.; Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA., Edfeldt K; Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden., Edwards AM; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca., Egner U; Nuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany., Frye SV; Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA.; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA., Fuchs SM; Institute for Protein Innovation Boston MA USA., Hall MD; National Center for Advancing Translational Sciences, National Institutes of Health Rockville Maryland 20850 USA., Hartung IV; Medicinal Chemistry, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany., Hillisch A; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany., Hitchcock SH; Takeda California 9625 Towne Centre Drive San Diego California 92121 USA., Homan E; Science for Life Laboratory, Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden., Kannan N; Institute of Bioinformatics and Department of Biochemistry and Molecular Biology, University of Georgia Athens GA USA., Kiefer JR; Genentech, Inc. 1 DNA Way South San Francisco California 94080 USA., Knapp S; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Kostic M; Department of Cancer Biology and Chemical Biology Program, Dana-Farber Cancer Institute 450 Brookline Ave Boston MA 02215 USA., Kubicek S; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria., Leach AR; European Molecular Biology Laboratory, European Bioinformatics Institute Wellcome Genome Campus, Hinxton Cambridgeshire CB10 1SD UK., Lindemann S; Strategic Innovation, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany., Marsden BD; Centre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.; Kennedy Institute of Rheumatology, NDORMS, University of Oxford UK., Matsui H; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited Fujisawa Kanagawa Japan., Meier JL; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health Frederick MD USA., Merk D; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.; LMU Munich, Department of Pharmacy, Chair of Pharmaceutical and Medicinal Chemistry 81377 Munich Germany., Michel M; Science for Life Laboratory, Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden., Morgan MR; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca., Mueller-Fahrnow A; Nuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany., Owen DR; Discovery Network Group, Pfizer Medicine Design Cambridge MA 02139 USA., Perry BG; Drugs for Neglected Diseases initiative 15 Chemin Camille Vidart Geneva 1202 Switzerland., Rosenberg SH; AbbVie North Chicago Illinois USA., Saikatendu KS; Global Research Externalization, Takeda California, Inc. 9625 Towne Center Drive San Diego CA 92121 USA., Schapira M; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.; Department of Pharmacology & Toxicology, University of Toronto Toronto Ontario M5S 1A8 Canada., Scholten C; Research and Development, Bayer AG, Pharmaceuticals 13353 Berlin Germany., Sharma S; Structural & Protein Sciences, Discovery Sciences, Janssen Research & Development 1400 McKean Rd Spring House PA 19477 USA., Simeonov A; National Center for Advancing Translational Sciences, National Institutes of Health Rockville Maryland 20850 USA., Sundström M; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden., Superti-Furga G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria.; Center for Physiology and Pharmacology, Medical University of Vienna Vienna Austria., Todd MH; School of Pharmacy, University College London London WC1N 1AX UK., Tredup C; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Vedadi M; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.; Department of Pharmacology & Toxicology, University of Toronto Toronto Ontario M5S 1A8 Canada., von Delft F; Centre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.; Diamond Light Source Ltd Harwell Science and Innovation Campus Didcot OX11 0QX UK.; Department of Biochemistry, University of Johannesburg Auckland Park 2006 South Africa.; Research Complex at Harwell Harwell Science and Innovation Campus Didcot OX11 0FA UK., Willson TM; Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA., Winter GE; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria., Workman P; CRUK ICR/Imperial Convergence Science Centre London SM2 5NG UK.; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research London SM2 5NG UK., Arrowsmith CH; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.; Princess Margaret Cancer Centre Toronto Ontario M5G 1L7 Canada.

Publikováno v: RSC medicinal chemistry [RSC Med Chem] 2021 Dec 03; Vol. 13 (1), pp. 13-21. Date of Electronic Publication: 2021 Dec 03 (Print Publication: 2022).

Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.

Autor: Zhao XY; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA. xiao-yan.zhao@bayer.com., Wilmen A; Biological Research, Bayer AG, 42113, Wuppertal, Germany., Wang D; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, 100084, China., Wang X; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, 100084, China., Bauzon M; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Kim JY; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Linden L; Biological Research, Bayer AG, 42113, Wuppertal, Germany., Li L; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, 100084, China., Egner U; Structural Biology, Bayer AG, 13342, Berlin, Germany., Marquardt T; Structural Biology, Bayer AG, 13342, Berlin, Germany., Moosmayer D; Structural Biology, Bayer AG, 13342, Berlin, Germany., Tebbe J; Biological Research, Bayer AG, 42113, Wuppertal, Germany., Glück JM; Biological Research, Bayer AG, 42113, Wuppertal, Germany., Ellinger P; Biological Research, Bayer AG, 42113, Wuppertal, Germany., McLean K; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Yuan S; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Yegneswaran S; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Jiang X; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Evans V; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Gu JM; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Schneider D; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Zhu Y; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Xu Y; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Mallari C; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Hesslein A; Biological Development, Bayer, Berkeley, CA, 94710, USA., Wang Y; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Schmidt N; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Gutberlet K; Pathology/Toxicology, Bayer AG, 42096, Wuppertal, Germany., Ruehl-Fehlert C; Pathology/Toxicology, Bayer AG, 42096, Wuppertal, Germany., Freyberger A; Pathology/Toxicology, Bayer AG, 42096, Wuppertal, Germany., Hermiston T; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Patel C; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Sim D; US Innovation Center, Bayer, 455 Mission Bay Blvd. South, San Francisco, CA, 94158, USA., Mosnier LO; The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA, 92037, USA. lmosnier@scripps.edu., Laux V; TRG-Cardiology/Hematology, Bayer AG, Aprather Weg 18a, 42113, Wuppertal, Germany. volker.laux@ime.fraunhofer.de.

Publikováno v: Nature communications [Nat Commun] 2020 Jun 12; Vol. 11 (1), pp. 2992. Date of Electronic Publication: 2020 Jun 12.

Eine systematische Übersichtsarbeit zu den Einflussfaktoren auf die berufliche Wiedereingliederung nach beruflichen Bildungsleistungen. (German)

Autor: Streibelt, M., Egner, U.

Publikováno v: Rehabilitation; Apr2013, Vol. 52 Issue 2, p111-118, 8p

Effectiveness of graded return to work after multimodal rehabilitation in patients with mental disorders. A propensity score analysis

Autor: Egner, U., Streibelt, M., Bürger, W., Bethge, M.

Publikováno v: In Annals of Physical and Rehabilitation Medicine July 2018 61 Supplement:e266-e266